Healthcare Industry News: UCB
News Release - March 3, 2008
Changes in UCB's Executive CommitteeJean-Pierre Pradier Executive Vice President, Corporate Human Resources to retire, Fabrice Enderlin is his successor.
Iris Löw-Friedrich, Executive Vice President, Development is new member of the Executive Committee.
BRUSSELS, BELGIUM, Mar 3, 2008--(Healthcare Sales & Marketing Network)--UCB today announced the appointment of Iris Löw-Friedrich, Executive Vice President, Development and Chief Medical Officer and Fabrice Enderlin, Executive Vice President, Corporate Human Resources as new members of UCB's Executive Committee with effect from March 1, 2008. Fabrice Enderlin is taking over the position from Jean-Pierre Pradier, who has announced he will be retiring on April 30, 2008.
Roch Doliveux, Chief Executive Officer of UCB said, "We are pleased to announce the two appointments to our Executive Committee. UCB is gaining two experts in their respective fields with a track record of accomplishments and extensive experience in the pharma industry. I am confident that Iris and Fabrice will make major contributions as we build UCB into the next generation biopharma leader." He further commented, "I would also like to pay particular tribute to Jean-Pierre Pradier who will be greatly missed. Jean-Pierre's contribution to the transformation of UCB has been pivotal. I thank him for his remarkable leadership in putting together an impressive human resources organization and laying the foundation for the new UCB. We wish him health, happiness and success in his much earned retirement."
Jean-Pierre Pradier joined UCB in 1997, at a time when UCB was expanding all over the world and need a globalised HR force. In January 2005, he was appointed member of the Executive Committee.
Fabrice Enderlin joined UCB in January 2008. Fabrice started his career during his study of Political Sciences at McDonald's and worked in the steel industry for Arcelor while completing his Master Degree in Human Resources. He joined the Pharma industry, first with Ciba, then Novartis as Vice President HR Pharma France. He joined GSK at the time of the merger, initially as Vice President HR France. From 2003 until end of 2007, Fabrice served as the Vice President HR with GSK Biologicals, the vaccines division of GSK, located in Belgium.
Prof. Dr. Iris Löw-Friedrich has been UCB's Senior Vice President, Development since September 1, 2007. In August 2001 Iris became a member of the SCHWARZ PHARMA AG Executive Board with responsibility for Research & Development. She has been a clinical professor for internal medicine at the University of Frankfurt am Main/Germany since 2000. Iris has significant experience and expertise in worldwide drug development within the Pharmaceutical industry. She held senior positions at Hoechst AG with global responsibility for clinical development programs in rheumatology, immunology and bone diseases as well as at BASF Pharma with responsibility for all pharma projects.
As of March 2008, UCB's Executive Committee, chaired by Roch Doliveux, Chief Executive Officer, has the following members, all of whom are Executive Vice Presidents: Fabrice Enderlin, Melanie Lee, Iris Löw-Friedrich, Jean-Pierre Pradier (until April 30, 2008), Bill Robinson, Detlef Thielgen and Bob Trainor.
Xavier Hormaechea, Public Affairs, UCB Group
T +32.2.559.9763, Xavier.email@example.com
Viviane Smeets, Corporate Communications, UCB Group
T +32.2.559.9346, Viviane.firstname.lastname@example.org
UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germany) is a member of the UCB Group.
UCB Forward-Looking Statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsEVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
UCB announces NAYZILAM(R) (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.